<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424801</url>
  </required_header>
  <id_info>
    <org_study_id>Vasointense</org_study_id>
    <nct_id>NCT00424801</nct_id>
  </id_info>
  <brief_title>Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris</brief_title>
  <official_title>Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cardiovascular Research Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if long-term vasodilatory treatment is more
      effective than the standard treatment in hypertensive patients with microvascular angina
      pectoris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hypertension frequently develop angina pectoris. This can be caused by either
      epicardial stenotic disease or, equally frequent, by increased resistance in small resistance
      vessels - microvascular dysfunction. This increased resistance is caused by a process called
      remodelling, where the existing material in the vessel wall is rearranged around a smaller
      lumen, whereas the sensitivity of the smooth muscle cells to agonist stimuli is unchanged.
      Under resting conditions the resistance is determined by both the tone in the smooth muscle
      cells in the vessel walls and the structure of the vessels themselves (RREST). Under
      hyperemic conditions the muscles relax and the resistance is determined only by vessel
      structure (RMIN).

      A literature survey of the various studies on this subject has shown that structural changes
      relates to tone rather than blood pressure. This suggests that resistance vessel structure
      will be normalized only by an antihypertensive treatment which normalizes RREST i.e. rely on
      vasodilatation as a cause of the antihypertensive effect more than reduction of cardiac
      output.

      The main hypothesis is, that it is possible to reverse the structural changes in the
      resistance vessels by vasodilatory treatment for eight months, thereby achieving lower
      coronary and peripheral minimal resistance (as determined by MRI and plethysmography,
      respectively), higher work capacity on exercise-ECG and less tendency to angina in these
      patients.

      We will include 80 patients with essential hypertension, angina pectoris CCS class II-III and
      signs of ischemia on exercise-ECG or myocardial SPECT, but without significant stenosis in
      angiography. The patients are randomised, in a parallel, open-label design, to either
      vasodilatory (lercanidipine, valsartan, doxazosin and nicorandil) or standard treatment
      (metoprolol, diltiazem and isosorbide mononitrate). The aim of treatment in both arms is BP
      below 120/80 and the protocol allows further add-on therapy to reach this goal. The patients
      will be followed for eight months with a titration period of two months. MRI,
      plethysmography, exercise-ECG and echocardiography will be performed before and after the
      study period. The primary endpoint is minimal coronary resistance as determined by MRI;
      secondary endpoints are peripheral vascular resistance as determined by plethysmography, work
      capacity and ischemia threshold on exercise-ECG or myocardial SPECT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal coronary resistance</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral vascular resistance</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work capacity</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia threshold</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Microvascular Angina</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Vasodilatory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine</intervention_name>
    <description>Individual titration, max. dose 20 mg OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Zanidip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Individual titration, max. dose 160 mg OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorandil</intervention_name>
    <description>Individual titration, max. dose 20 mg BD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Angicor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Individual titration, max. dose 4 mg OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Doxazosin &quot;Stada&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidin</intervention_name>
    <description>Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Moxonidin &quot;Alpharma&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pindolol</intervention_name>
    <description>Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Visken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride, hydrochlorothiazide</intervention_name>
    <description>Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Sparkal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertension

          -  angina pectoris CCS class II-IV

          -  objective signs of ischemia on exercise-ECG or myocardial SPECT

          -  no significant stenosis on angiography (minimal lumen diameter &gt;50% of relevant
             reference segment)

        Exclusion Criteria:

          -  known allergy to any study medication

          -  abnormal lab tests of clinical significance

          -  valvular disease of haemodynamic significance

          -  known secondary hypertension

          -  atrial fibrillation or other significant arrythmias

          -  myocardial infarction &lt; 30 days before inclusion

          -  resting angina &lt; one week before inclusion

          -  known endocrine disease, nephropathy or hepatic disease

          -  present malignant disease

          -  pregnancy

          -  fertile women not using safe contraceptives &gt; 6 months before inclusion. Use of
             contraceptives must continue 1 month after completion or retraction from the study

          -  body mass index &gt; 30

          -  significant chronic obstructive lung disease (FEV1 &lt; 1.5 l)

          -  participant in another study including test medicine

          -  present treatment with dipyridamole

          -  present treatment with phosphodiesterase-5-inhibitors that the patient does not want
             to discontinue during the study period

          -  heart transplanted patients

          -  patients with magnetizable metallic implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael N Præstholm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kent L Christensen, MD, DrMSc</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus Hospital, medical-cardiologic dept. A</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Yong Kim, MD, DrMSc</last_name>
    <role>Study Director</role>
    <affiliation>Skejby Hospital, cardiologic dept. B</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Erik Bøtker, MD, DrMSc</last_name>
    <role>Study Director</role>
    <affiliation>Skejby Hospital, cardiologic dept. B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kent Lodberg Christensen, DMSc</name_title>
    <organization>Aarhus Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Nicorandil</mesh_term>
    <mesh_term>Pindolol</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

